RCT | LMWH does not increase live birth rates in women with thrombophilia and recurrent miscarriage

Heparin for women with recurrent miscarriage and inherited thrombophilia (ALIFE2): an international open-label, randomised controlled trial – The Lancet (link to abstract – $ for full-text)

News Release: Study recommends ending heparin use for women with recurrent miscarriage and inherited thrombophilia – National Institute for Health and Care Research

Commentary on Twitter (thread – click for more)

New study: Many women with recurrent miscarriage are tested for inherited thrombophilia. If confirmed positive, daily subcutaneous low-molecular-weight heparin (LMWH) is given.

This is despite an absence of evidence that such treatment is beneficial ? https://t.co/0IuFhvjlZr

— The Lancet (@TheLancet) June 2, 2023